Aqemia
Founded Year
2019Stage
Grant | AliveTotal Raised
$108.31MLast Raised
$7.4M | 7 mos agoRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-115 points in the past 30 days
About Aqemia
Aqemia focuses on transforming the drug discovery process. The company offers technology that combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a rapidly growing pipeline of new drug candidates. It primarily sells to the pharmaceutical industry. It was founded in 2019 and is based in Paris, France.
Loading...
ESPs containing Aqemia
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The quantum computing for drug discovery market leverages quantum algorithms and computing infrastructure to accelerate pharmaceutical research and development. These providers offer quantum-enhanced solutions for molecular simulation, drug candidate identification, binding prediction, and protein folding analysis that surpass classical computing capabilities. Companies combine quantum computing w…
Aqemia named as Challenger among 15 other companies, including IBM, Microsoft, and SandboxAQ.
Aqemia's Products & Differentiators
Drugs
At AQEMIA, we invent small molecule pre-clinical candidates for therapeutic targets that are currently unexplored or remain undruggable
Loading...
Research containing Aqemia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aqemia in 9 CB Insights research briefs, most recently on Sep 19, 2025.
Sep 19, 2025 report
Book of Scouting Reports: AI Drug Discovery
Aug 22, 2025 report
Book of Scouting Reports: Generative AI in Healthcare & Life Sciences
May 23, 2025
The AI in drug R&D market map
Jan 11, 2024
The generative AI in healthcare market map
Jan 8, 2024
4 applications of generative AI in drug R&D
May 9, 2023
7 applications of generative AI in healthcareExpert Collections containing Aqemia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aqemia is included in 7 Expert Collections, including Artificial Intelligence (AI).
Artificial Intelligence (AI)
16,578 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI 100 (All Winners 2018-2025)
100 items
Generative AI 50
50 items
CB Insights' list of the 50 most promising private generative AI companies across the globe.
Generative AI
2,951 items
Companies working on generative AI applications and infrastructure.
Latest Aqemia News
Oct 7, 2025
L'agefi Ayomi réalise une acquisition et améliore son accompagnement à la levée de fonds En rachetant Meeya, la fintech spécialisée dans le financement en capital compte accélérer ses processus et se prépare à devenir une néobanque pour les entreprises. Publié le Plus d'articles du même thème Yves-Marc Le Réour Après le succès de son augmentation de capital massive, le groupe danois confirme le calendrier de livraison de ses projets américains Sunrise Wind et Revolution Wind. Petra Norrbin Une révolution technologique arrive avec l'identité numérique réutilisable qui offre aux utilisateurs la possibilité de centraliser et sécuriser leurs données d’identité vérifiées et de les partager de manière fluide et conforme auprès de multiples prestataires. Alexandra Oubrier La fintech spécialisée dans les cartes carburants et dans les cartes achats a été confirmée comme fournisseur du secteur public. Une décision importante qui illustre une prise de conscience du rôle de l’Etat dans la croissance des entreprises innovantes. Sujets d'actualité 3 octobre 2025 à 11:47 AM · Pourquoi favoriser une approche obligataire à rendement absolu ? PARTENARIAT PARTENARIAT PARTENARIAT Par Alteryx « L’Alteryx Analytics Summit sera l’évènement phare dédié à l’usage de la donnée dans les entreprises » PARTENARIAT Par AMUNDI ETF Une opportunité trop grande pour être ignorée : le secteur de la défense en plein essor en Europe A lire sur ... Dinah Cohen Après avoir flanché sur les hausses d'impôts pour plus de justice fiscale, le bloc central lève désormais le tabou d'une suspension de la réforme des retraites, jugée préférable à une dissolution Les 100 qui font l'IA en Europe 2025 Grégoire Arnould Issue de l'Ecole normale supérieure et du CNRS, Aqemia a levé plus de 100 millions d'euros, signé un partenariat majeur avec Sanofi et ouvert un bureau à Londres début 2025. Tribune libre Maria Repko « Le projet de budget 2026 de l’Ukraine n’est pas seulement un plan financier national. C’est aussi une invitation, adressée à l’Europe, à penser sur le long terme et à enfin traiter l’Ukraine comme faisant partie de sa propre architecture », prévient Maria Repko, directrice adjointe du Centre for Economy Strategy de Kiev
Aqemia Frequently Asked Questions (FAQ)
When was Aqemia founded?
Aqemia was founded in 2019.
Where is Aqemia's headquarters?
Aqemia's headquarters is located at 1 Boulevard Pasteur, Paris.
What is Aqemia's latest funding round?
Aqemia's latest funding round is Grant.
How much did Aqemia raise?
Aqemia raised a total of $108.31M.
Who are the investors of Aqemia?
Investors of Aqemia include France 2030, Elaia Partners, Wendel, Bpifrance, Cathay Innovation and 8 more.
Who are Aqemia's competitors?
Competitors of Aqemia include Variational AI, Insilico Medicine, Cradle, Biomatter, Valence Labs and 7 more.
What products does Aqemia offer?
Aqemia's products include Drugs.
Loading...
Compare Aqemia to Competitors
Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
Cradle focuses on protein engineering in the biotechnology sector, using machine learning to optimize protein sequences. It provides tools for designing improved variants of target proteins, integrating laboratory data, and predicting performance to support research and development. Its solutions are relevant for biotech teams working on various applications, including therapeutics, enzymes, vaccines, peptides, and antibodies. It was founded in 2021 and is based in Amsterdam, Netherlands.
InstaDeep focuses on delivering artificial intelligence (AI)-powered decision-making systems for various enterprise sectors. The company offers solutions that leverage computing, deep learning, and reinforcement learning to address challenges in industries such as biology, logistics, electronic design, and energy. Its products and services are designed to help the capabilities of businesses by providing advanced AI tools and research insights. InstaDeep was formerly known as Digital Ink Group. It was founded in 2014 and is based in London, United Kingdom.
YDS Pharmatech is a company focused on drug discovery in the pharmaceutical industry. The company offers a platform for the design of new drug candidates, utilizing structure-based de novo drug design and evolutionary AI to accelerate the drug discovery process. YDS Pharmatech primarily serves the pharmaceutical industry. It was founded in 2020 and is based in Albany, New York.
Variational AI is a company focused on drug discovery utilizing generative AI within the biopharmaceutical sector. The company offers Enki, a platform that generates novel drug-like small molecules based on user-defined therapeutic product profiles (TPP) without requiring prior data. Variational AI primarily serves the biopharmaceutical industry, collaborating with partners to develop new therapeutics. It was founded in 2019 and is based in Vancouver, Canada.
Endel specializes in creating personalized sound environments designed to reduce stress, improve sleep, and enhance productivity, utilizing neuroscience and circadian rhythm science. The company offers a range of products, including apps for iOS and Android, integrations with Alexa, and a standalone Apple Watch app, all featuring adaptive soundscapes that respond to real-time inputs such as time of day, weather, and heart rate. It was founded in 2018 and is based in Berlin, Germany.
Loading...